The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized.The pipeline prioritization is expected to result in a reduction in workforce of approximately
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven s lead investigational drug from its Molecular Degrader of Extracellular.
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.